Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Dosage form for treating cardiovascular diseases|
|Abstract:||An osmotic device is disclosed comprising a first composition, and a second composition with the beneficial drug isradipine in the first composition.|
|Inventor(s):||Ayer; Atul D. (Palo Alto, CA), Swanson; David R. (Palo Alto, CA), Kuczynski; Anthony L. (Palo Alto, CA)|
|Assignee:||Alza Corporation (Palo Alto, CA)|
|Patent Claims:||1. A composition for use in an osmotic device, said composition comprising about 2 weight percent to 30 weight percent of isradipine, a polyethylene oxide comprising a molecular weight of about 200,000 to about 300,000 and a hydroxypropylemthylecellulose comprising a number average molecular weight of about 9,000 to 15,000.|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.